478362-98-0

Upstream product

• 187807-02-9 C₅₂H₈₀N₆O₁₂ 

Downstream Products

• 478363-03-0 Boc-Map-Hmp-Gly-N-Me-L-Leu-Gly-N-Me-L-Val-O,N-diMe-L-Tyr-Ibu-N-Me-L-Ala 
• 213530-40-6 lyngbyastatin 1 
• 213530-40-6 Ibu-epilyngbyastatin 1 
• 478363-01-8 Boc-Map-Hmp-Gly-N-Me-L-Leu-Gly-N-Me-L-Val-O,N-diMe-L-Tyr-Ibu-N-Me-L-Ala-OBn 

Relevant academic research and scientific papers

Lyngbyastatin 1 and Ibu-epilyngbyastatin 1: Synthesis, stereochemistry, and NMR line broadening

The synthesis of a lyngbyastatin 1-Ibu-epilyngbyastatin 1 mixture combined with NMR and molecular modeling studies proved that natural lyngbyastatin 1 was only one Ibu epimer rather than a mixture of both and that the configuration of this epimer in the Ibu unit was R. The substance isolated with lyngbyastatin 1 was Ibu-epidolastatin 12. The extreme broadness in the proton NMR spectra of lyngbyastatin 1 and Ibu-epidolastatin 12 was exchange broadening due to rotation about the Ibu-Ala amide bond. It was a consequence of (1) a small energy difference between the cis and trans forms of this bond, (2) a substantial difference in conformation between these forms, and (3) a lowered barrier between them compared to most amide bonds (due to steric hindrance). The synthetic lyngbyastatin 1-Ibu-epilyngbyastatin 1 mixture had significant activities against cancer cells and in stimulating actin polymerization, but was less active than dolastatin 11 in all assays.